Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji(Institute of Cancer Research), Philippe Aftimos(Institut Jules Bordet), Fiona Thistlethwaite(The Christie NHS Foundation Trust), Carla M.L. van Herpen(Radboud University Nijmegen), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Jill J.J. Geenen(The Netherlands Cancer Institute), Sylvie Rottey(Ghent University Hospital), Elisabeth G.E. de Vries(Karolinska University Hospital), Marta Gil-Martín(Institut Català d'Oncologia), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Cristina Saura(Vall d'Hebron Hospital Universitari), Simon Lord(University of Oxford), N.P. Koper(Synthon (Netherlands)), Ellen C.M. Mommers(Johns Hopkins University), Víctor Moreno, Ferry A.L.M. Eskens(Erasmus MC), Valentina Boni
Cited by 564
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k